Whitepapers/App Notes/Posters

Application note: High-throughput fluorescence-based mAbs aggregation analysis workflow

Posted: 5 January 2021 | | No comments yet

Modern biologics development relies on the screening of 100s – 1000s of monoclonal antibody (mAb) variants to identify lead development candidates with optimal properties such as affinity, specificity, immunogenicity, and glycosylation.

Antibody aggregation can be an unintended side-effect of these optimizations as it is influenced by molecular attributes as well as those of the expression host. It is controlled and monitored as a critical quality attribute (1). The ability to rapidly assess the propensity of mAb to aggregate is thus a core requirement of modern pharmaceutical development.











    To read this supplement in full, please complete the form below:

     











    Would you like to be contacted by an Agilent expert to learn more about Agilent Cary Eclipse? *

    YesNo

     


    Yes, I would like to receive email updates about Agilent products, services and events. For full details of how we will treat your information please view our privacy policy: www.agilent.com/home/privacy-policy

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Related topics

    ,

    Related organisations

    ,

    Send this to a friend